Finance

Lists
AJANTPHARM:NSE
Ajanta Pharma Ltd
3 330,00 INR
+0,05%
(+1,80) 1D
14 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AJANTPHARM...
Open
3 328,20 INR
High
3 377,20 INR
Low
3 269,90 INR
Mkt. cap
417,30 მლრ.
Avg. vol.
91,75 ათ.
Volume
74,87 ათ.
Dividend
1,59%
Quarterly dividend
13,25 INR
Ex-dividend date
5 აგვ. 2026
P/E ratio
36,66
52-wk high
3 796,00 INR
52-wk low
2 380,20 INR
EPS
90,83 INR
Shares outstanding
88,45 მლნ.
No. of employees
10 ათ.
Open
3 328,20 INR
High
3 377,20 INR
Low
3 269,90 INR
Mkt. cap
417,30 მლრ.
Avg. vol.
91,75 ათ.
Volume
74,87 ათ.
Dividend
1,59%
Quarterly dividend
13,25 INR
Ex-dividend date
5 აგვ. 2026
P/E ratio
36,66
52-wk high
3 796,00 INR
52-wk low
2 380,20 INR
EPS
90,83 INR
Shares outstanding
88,45 მლნ.
No. of employees
10 ათ.
News stories
From web sources and news partners
Profile
Ajanta Pharma Limited is an Indian multinational pharmaceutical company. The company operates in India, the United States, and over 30 countries across Africa, Southeast Asia, West Asia, and the CIS. It was established in 1973.. Wikipedia
About Ajanta Pharma Ltd
CEO-
Employees10,4 ათ.
Founded1973
Headquarters-
SectorPharmaceutical industry
Last report
30 ივლ. 2026
Fiscal period
Q1 2027
26,72 INR / 22,90 INR
+16,68%beat
Revenue / Est. (INR)
16,26 მლრდ. / 15,30 მლრდ.
+6,26%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
13,54 მლრდ.
13,75 მლრდ.
14,22 მლრდ.
16,26 მლრდ.
Cost of goods sold
3,17 მლრდ.
2,86 მლრდ.
3,85 მლრდ.
3,28 მლრდ.
Cost of revenue
3,17 მლრდ.
2,86 მლრდ.
3,85 მლრდ.
3,28 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,17 მლრდ.
3,31 მლრდ.
3,50 მლრდ.
3,81 მლრდ.
Operating expense
7,11 მლრდ.
7,50 მლრდ.
7,05 მლრდ.
8,88 მლრდ.
Total operating expenses
10,28 მლრდ.
10,36 მლრდ.
10,90 მლრდ.
12,16 მლრდ.
Operating income
3,26 მლრდ.
3,39 მლრდ.
3,32 მლრდ.
4,10 მლრდ.
Other non operating income
197,10 მლნ.
164,20 მლნ.
-447,90 მლნ.
204,30 მლნ.
EBT including unusual items
3,41 მლრდ.
3,59 მლრდ.
3,47 მლრდ.
4,47 მლრდ.
EBT excluding unusual items
3,41 მლრდ.
3,59 მლრდ.
4,42 მლრდ.
4,47 მლრდ.
Income tax expense
806,20 მლნ.
848,30 მლნ.
804,10 მლნ.
1,13 მლრდ.
Effective tax rate
23,66%
23,66%
23,17%
25,20%
Other operating expenses
3,51 მლრდ.
3,76 მლრდ.
3,09 მლრდ.
4,63 მლრდ.
Net income
2,60 მლრდ.
2,74 მლრდ.
2,67 მლრდ.
3,34 მლრდ.
Net profit margin
19,22%
19,91%
18,76%
20,56%
Earnings per share
20,82
21,91
21,34
26,72
Interest and investment income
-
-
516,00 მლნ.
-
Interest expense
-33,90 მლნ.
-51,00 მლნ.
-23,60 მლნ.
-31,80 მლნ.
Net interest expenses
-33,90 მლნ.
-51,00 მლნ.
492,40 მლნ.
-31,80 მლნ.
Depreciation and amortization charges
429,70 მლნ.
435,10 მლნ.
453,70 მლნ.
445,00 მლნ.
EBITDA
3,68 მლრდ.
3,70 მლრდ.
3,70 მლრდ.
4,49 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები